![]() Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE (2017) Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. Orr RK (1999) The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis. Arch Surg 141(9):867–874įisher CS, Margenthaler JA, Hunt KK, Schwartz T (2020) The landmark series: axillary management in breast cancer. Konkin DE, Tyldesley S, Kennecke H, Speers CH, Olivotto IA, Davis N (2006) Management and outcomes of isolated axillary node recurrence in breast cancer. Sakorafas GH, Tsiotou AG, Balsiger BM (2000) Axillary lymph node dissection in breast cancer: current status and controversies, alternative strategies and future perspectives. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth W, Blumencranz W, Leitch M, Saha S, McCall LM, Morrow M (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Clin Breast Cancer 18(6):e1251–e1259ĭonker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Yan M, Abdi MA, Falkson C (2018) Axillary management in breast cancer patients: a comprehensive review of the key trials. Kaviani A, Sodagari N, Sheikhbahaei S, Eslami V, Hafezi-Nejad N, Safavi A, Noparast M, Fitoussi A (2013) From radical mastectomy to breast-conserving therapy and oncoplastic breast surgery: a narrative review comparing oncological result, cosmetic outcome, quality of life, and health economy. Veronesi U, Stafyla V, Luini A, Veronesi P (2012) Breast cancer: from “maximum tolerable” to “minimum effective” treatment. Watkins EJ (2019) Overview of breast cancer. We have proposed a treatment algorithm to follow, in addition to the local/regional guideline recommendations, before planning the treatment strategy for breast cancer patients. The impact of ALND on locoregional recurrence (LR), overall survival (OS), and disease-free survival (DFS) outcomes in SLNs positive patients has been evaluated. The timing and accuracy of SLNB in patients who are receiving neoadjuvant chemotherapy (NACT) for breast cancer have also been discussed. ![]() ![]() The various tracer used for identification of SLN and the best combination available for staging the axilla with high accuracy and low risk of false negativity has been assessed. In this review, we have discussed the observations from various trials and guidelines recommendations on the need or omission of ALND in patients with breast cancer undergoing SLNB. Sentinel lymph node biopsy (SLNB) may spare many patients the need for axillary lymph node dissection (ALND) as well as the morbidities associated with ALND. Axillary staging is one of the most important prognostic variables in breast cancer treatment. For the proper management of breast cancer, it is essential to differentiate clinically node-positive or clinically node-negative patients but having a positive sentinel lymph node (SLN). However, the management of the axilla has been a debatable topic since many decades. Breast cancer treatment approaches have changed from “maximum tolerable” to “minimum effective” with the same cure rates and cosmesis but better quality of life (QoL). In 2018, one in four newly detected cancer in women was breast cancer in India. Breast cancer is one of the three most common cancers occurring worldwide.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |